Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | KAT2B | Q92831 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3689858 | 0.85 | BRD4 (0.41) | BRD4SMN1; SMN2CHRNB2CHRNA4KMT2A | |
| SCHEMBL5727783 | 0.83 | BRD4 (0.50) | BRD4CHRNB2CHRNA4KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL3693041 | 0.83 | BRD4 (0.39) | BRD4SMN1; SMN2CHRNB2CHRNA4KMT2A | |
| SCHEMBL25333482 | 0.74 | KMT2A (0.48) | KMT2A | |
| SCHEMBL12994229 | 0.72 | BRD4 (0.36) | BRD4CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL14441118 | 0.72 | BRD4 (0.35) | BRD4 | |
| SCHEMBL24483517 | 0.71 | CHRNB2 (0.58) | BRD4CHRNB2CHRNA4KMT2ACHRNB4 | |
| SCHEMBL24483210 | 0.71 | CHRNB2 (0.58) | BRD4CHRNB2CHRNA4KMT2ACHRNB4 | |
| SCHEMBL5118393 | 0.70 | BRD4 (0.40) | BRD4SMN1; SMN2CHRNB2CHRNA4KMT2A | |
| SCHEMBL24035543 | 0.69 | CHRNB2 (0.57) | BRD4CHRNB2CHRNA4KMT2ACHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275241-A1 | Polymorphic Forms of Dolasetron Base and Processes of Preparing Dolasetron Base, Its Polymorphic Forms and Salt Thereof | USV LIMITED (IN) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275241-A1 | Polymorphic Forms of Dolasetron Base and Processes of Preparing Dolasetron Base, Its Polymorphic Forms and Salt Thereof | CYP4A11, CYP3A43, VKORC1 | BRD4 3815/4885SMN1; SMN2 4047/4885CHRNB2 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.